Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
RALEIGH, N.C., Dec. 23, 2016 -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to Phase IV contract research organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mr. Macdonald’s presentation is scheduled for Wednesday, Jan. 11, 2017, at 10:00 a.m. PST.
Links to INC Research’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: [email protected] Press/Media Contact: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 763-1380 Email: [email protected]
